These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [The quest for an HIV vaccine]. Girard MP Bull Acad Natl Med; 2005 May; 189(5):831-44; discussion 844. PubMed ID: 16433455 [TBL] [Abstract][Full Text] [Related]
25. Social impact of preventive HIV vaccine clinical trial participation: a model of prevention, assessment and intervention. Allen M; Lau CY Soc Sci Med; 2008 Feb; 66(4):945-51. PubMed ID: 18162272 [TBL] [Abstract][Full Text] [Related]
26. Large-scale HIV vaccine trial to begin this summer. Highleyman L BETA; 1998 Jul; ():3. PubMed ID: 11365557 [TBL] [Abstract][Full Text] [Related]
27. First AIDS vaccine tested did not protect, but gives scientific leads. James JS AIDS Treat News; 2003 Mar; (389):6. PubMed ID: 12712937 [TBL] [Abstract][Full Text] [Related]
28. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA. WHO/UNAIDS/IAVI International Expert Group AIDS; 2007 Feb; 21(4):539-46. PubMed ID: 17301582 [TBL] [Abstract][Full Text] [Related]
29. AIDSVAX results: an answer, or just more questions? Johnston R AIDS Patient Care STDS; 2003 Feb; 17(2):47-51. PubMed ID: 12650142 [TBL] [Abstract][Full Text] [Related]
30. Should developing countries be testing grounds for vaccines rejected by the USA? AIDS Anal Afr; 1994; 4(4):2. PubMed ID: 12288157 [TBL] [Abstract][Full Text] [Related]
31. NIAID collaborates with VaxGen on vaccine studies. AIDS Patient Care STDS; 1998 Nov; 12(11):874. PubMed ID: 11362049 [No Abstract] [Full Text] [Related]
32. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Karnasuta C; Paris RM; Cox JH; Nitayaphan S; Pitisuttithum P; Thongcharoen P; Brown AE; Gurunathan S; Tartaglia J; Heyward WL; McNeil JG; Birx DL; de Souza MS; Vaccine; 2005 Mar; 23(19):2522-9. PubMed ID: 15752839 [TBL] [Abstract][Full Text] [Related]
33. Recent advances in AIDS vaccine research and development. Johnston MI; Noe JS; Killen JY AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S317-23. PubMed ID: 7865330 [TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. Nitayaphan S; Pitisuttithum P; Karnasuta C; Eamsila C; de Souza M; Morgan P; Polonis V; Benenson M; VanCott T; Ratto-Kim S; Kim J; Thapinta D; Garner R; Bussaratid V; Singharaj P; el-Habib R; Gurunathan S; Heyward W; Birx D; McNeil J; Brown AE; J Infect Dis; 2004 Aug; 190(4):702-6. PubMed ID: 15272397 [TBL] [Abstract][Full Text] [Related]
35. VaxGen AIDS vaccine clears phase III safety hurdle again. AIDS Read; 2001 May; 11(5):246. PubMed ID: 11392687 [No Abstract] [Full Text] [Related]
36. The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand. Andersson KM; Stover J Vaccine; 2011 Aug; 29(36):6092-9. PubMed ID: 21703322 [TBL] [Abstract][Full Text] [Related]
37. The challenges of HIV vaccine development and testing. Burgers WA; Williamson C Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):277-91. PubMed ID: 15778116 [TBL] [Abstract][Full Text] [Related]
38. HIV vaccines for prevention of infection and disease in humans. Dolin R Infect Dis Clin North Am; 2000 Dec; 14(4):1001-16. PubMed ID: 11144638 [TBL] [Abstract][Full Text] [Related]
39. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. Pitisuttithum P; Berman PW; Phonrat B; Suntharasamai P; Raktham S; Srisuwanvilai LO; Hirunras K; Kitayaporn D; Kaewkangwal J; Migasena S; Sheppard HW; Li E; Chernow M; Peterson ML; Shibata R; Heyward WL; Francis DP J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1160-5. PubMed ID: 15319676 [TBL] [Abstract][Full Text] [Related]